Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly and Daiichi Sankyo are on track to submit an NDA for their experimental antiplatelet drug prasugrel by the end of the year despite mixed study results that showed it is more effective than Plavix but with a worrisome bleeding profile.